Oleg Nodelman - 19 Sep 2023 Form 4/A - Amendment Insider Report for Nuvation Bio Inc. (NUVB)

Reporting relationship: Director
Issuer ticker: NUVB
Reported as of: 19 Sep 2023
Net transaction value: +$6,692,265
SEC form: 4/A - Amendment
Accepted by SEC: 22 Sep 2023, 15:44:37 UTC
Original report date: 21 Sep 2023
Prior SEC filing: 21 Sep 2023
Next SEC filing: 18 Feb 2025
Source filing: View source filing
Reporting owner signature: Oleg Nodelman, individually and as Manager of EcoR1 Capital, LLC and Biotech Opportunity GP, LLC

Key filing fact

Oleg Nodelman filed Form 4/A - Amendment for Nuvation Bio Inc. (NUVB) on 22 Sep 2023.

Key facts

This page summarizes Oleg Nodelman's Form 4/A - Amendment filing for Nuvation Bio Inc. (NUVB).
3 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 22 Sep 2023, 15:44.

Change

Previous filing in this sequence was filed on 21 Sep 2023.
Current net transaction value: +$6,692,265.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

NUVB transaction

Class A Common Stock

Purchase

Transaction value: $6,460,637
Shares: +5,143,000
Change %: +70%
Price: $1.26
Shares after: 12,504,675
Date: 19 Sep 2023
Ownership: See Notes
Footnotes: F1, F2, F3

NUVB transaction

Class A Common Stock

Purchase

Transaction value: $159,490
Shares: +117,100
Change %: +0.94%
Price: $1.36
Shares after: 12,621,775
Date: 20 Sep 2023
Ownership: See Notes
Footnotes: F1, F2, F4

NUVB transaction

Class A Common Stock

Purchase

Transaction value: $72,138
Shares: +53,000
Change %: +0.42%
Price: $1.36
Shares after: 12,674,775
Date: 21 Sep 2023
Ownership: See Notes
Footnotes: F1, F2, F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

EcoR1 Capital, LLC ("EcoR1") is the investment adviser to EcoR1 Capital Fund, L.P. ("Capital Fund"), EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The reporting persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.

Footnote F2

Qualified Fund is the record holder of these securities.

Footnote F3

On 9/21/2023, the reporting persons filed a Form 4 (the "Original Form 4") that inadvertently identified the date of this transaction as 2/19/2023. As reported in this amendment, the date of this transaction was 9/19/2023. The Original Form 4 also inadvertently identified the date of the earliest transaction reported in the Original Form 4 as 2/19/2023. As reported in this amendment, the date of the earliest transaction was 9/19/2023.

Footnote F4

The Original Form 4 inadvertently identified the date of this transaction as 2/20/2023. As reported in this amendment, the date of this transaction was 9/20/2023.

Footnote F5

Original Form 4 inadvertently identified the date of this transaction as 2/21/2023. As reported in this amendment, the date of this transaction was 9/21/2023.